BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc.

BCRXNYSE / NASDAQHealthcareSmall cap

$7.22-$0.10 (-1.4%)

Last close · Data as of Nov 20, 2026

Market cap
$2.2B
P/E
8.2x
EV / EBITDA
7.2x
Revenue
$874.8M
Net margin
30.2%
ROCE
107.2%

+2.7% over the last year

BioCryst Pharmaceuticals, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-9.1%
3M
-25.3%
6M
-17.4%
1Y
+2.7%
5Y
-39.3%

52-week range

Day change -$0.10 (-1.4%) from $7.32 to $7.22 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in BCRX, bought on each weekday since 2021.

News & filings

What BioCryst Pharmaceuticals filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernShareholders' equity is negative: liabilities exceed assets.

Strengths (1)

  • Revenue grew 94.1% in fiscal 2025.
  • Shareholders' equity is negative, so return on equity and debt to equity are not shown.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE.

Read moreShow less

BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Sector
Healthcare
Shares outstanding
209.4M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$2.2B
P/E
8.2x
P/B
-18.1x
EV / EBITDA
7.2x
EV / Sales
2.9x
P/S
2.5x
52-week high
$11.11
52-week low
$6.24

Profitability

Operating margin
39.0%
Net margin
30.2%
EBITDA margin
39.7%
ROE
-221.4%
ROCE
107.2%
ROIC
148.6%
ROA
51.3%
Asset turnover
1.70

Growth

Revenue
$874.8M
Revenue growth, 1Y
94.1%
Revenue CAGR, 3Y
47.8%
Net profit growth, 1Y
-396.9%
Free cash flow
$344.9M

Solvency

Current ratio
2.06
Debt / Equity
-3.68
Debt / Assets
0.85
CFO / Net profit
1.32
Cash / Market cap
4.2%

Where the revenue went

Of every $100 of FY2025 revenue, $30 was left as net income.

BioCryst Pharmaceuticals, Inc. income statement flow, FY2025
BioCryst Pharmaceuticals, Inc. income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$19.1M
RevenueGross profit$855.8M
Gross profitOperating expenses$514.8M
Gross profitOperating income$341.0M
Operating incomePretax income$267.4M
Operating incomeInterest and other expense$73.6M
Pretax incomeTax and other$3.5M
Pretax incomeNet income$263.9M

Revenue and net profit

Revenue grew 94.1% in FY2025; net profit is the dashed line.

BioCryst Pharmaceuticals, Inc. revenue and net profit by fiscal year
BioCryst Pharmaceuticals, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$270.8M-$247.1M
FY2023$331.4M-$226.5M
FY2024$450.7M-$88.9M
FY2025$874.8M$263.9M

Cash flows

FY2025: $347.4M from operations, $344.9M free after investment (dashed).

BioCryst Pharmaceuticals, Inc. operating and free cash flow by fiscal year
BioCryst Pharmaceuticals, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$161.8M-$163.2M
FY2023-$95.1M-$97.3M
FY2024-$52.0M-$53.1M
FY2025$347.4M$344.9M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$874.8M+94.1%1Y
EBITDA
$347.7M+2,614.3%1Y
Net profit
$263.9M
Cash from operations
$347.4M
Free cash flow
$344.9M
Revenue CAGR, 3Y
47.8%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$874.8M$347.7M$263.9M$344.9M-221.4%+94.1%-396.9%

Monthly returns

Month-by-month returns of BCRX across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$514.2M
Liabilities$633.3M
Equity-$119.2M
Paid-in capital$1.4B
Retained earnings-$1.5B

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; BCRX highlighted.

P/E against peers

BCRX trades at 8.2x earnings against a peer median of -14.3x.

  1. BioCryst Pharmaceuticals, Inc. (this company)8.2x

EV / Sales, for the companies without earnings

Not shown (no positive earnings and no EV / Sales): Mineralys Therapeutics, Inc., Enliven Therapeutics, Inc., Kodiak Sciences Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
BioCryst Pharmaceuticals, Inc.BCRXthis company$2.2B8.2x-18.1x-221.4%7.2x
Immunome, Inc.IMNM$2.2B-10.5x3.5x-33.5%-7.1x
Mineralys Therapeutics, Inc.MLYS$2.2B-14.3x3.4x-23.9%—
Enliven Therapeutics, Inc.ELVN$2.2B-20.8x4.7x-22.6%-17.3x
Kodiak Sciences Inc.KOD$2.1B—13.6x-146.1%—
Aurinia Pharmaceuticals Inc.AUPH$2.1B7.3x3.6x49.4%15.2x
Clover Health Investments, Corp.CLOV$2.1B-24.6x6.8x-27.7%—
NovoCure LimitedNVCR$2.1B—6.1x-40.0%—
Intellia Therapeutics, Inc.NTLA$2.1B—3.1x-61.5%—
Peer median—-14.3x4.2x-30.6%-7.1x

Year-to-date ROI

BCRX since 1 January, against earlier years.

Historical volatility

BCRX's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

BioCryst Pharmaceuticals, Inc. operating margin by fiscal year
BioCryst Pharmaceuticals, Inc. operating margin by fiscal year
DateOperating margin
FY2022-54.8%
FY2023-31.3%
FY2024-0.6%
FY202539.0%
LineFY2025
Cost of revenueCost Of Revenue$19.1M
Gross profitGross Profit$855.8M
Operating expensesOperating Expense$514.8M
Research and developmentResearch And Development$166.1M
Selling, general and administrativeSelling General And Administration$348.6M
Total expensesTotal Expenses$533.9M
Pretax incomePretax Income$267.4M

Learn while you research

Academy chapters picked for BioCryst Pharmaceuticals, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Value InvestingA P/E of 8.2 could be a value opportunity, or a value trap. Know the difference.7 min read
  3. 03 Growth Investing94% revenue growth is in the top tier, learn how to value growth.7 min read
  4. 04 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  5. 05 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  6. 06 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
Browse the full Equiscale Academy →